亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Novel Aerosolized Treatment for Asthma

詳細技術說明
None
*Abstract
Investigators have developed microspheres carrying antisense DNA technology targeted to specific molecules vitally involved in allergic asthma. These microspheres can be administered via an aerosolized formulation. The microsphere encapsulated anti-sense molecules orchestrate an anti-inflammatory response by considerably decreasing the pro-inflammatory cytokines secreted by mast cells and dendritics cell in the lung. Moreover, the microspheres were found to reach a large populationof lung cells following intratracheal instillation.Applications1) Inhaled treatment for reversal and prevention of asthma2) May be used to treat other systemic allergic reactions mediated by IgEAdvantages1) Microsphere formulation extends half-life of oligonucleotides2) Effective concentration of molecules accumulate in lung target tissue3) Appears to have less toxicity than humanized IgE antibodiesStage of Development1) Data from in vitro cell studies available2) Animal studies are underwayBackgroundAllergic asthma is a complex inflammatory disease of the lungs characterized by variable airflow obstruction, airway hyperresponsiveness (AHR) and airway inflammation. The inflammatory process consists of a chronic infiltration by mast cells, basophils, eosinophils, dendritic cells and BIT-lymphocytes, each playing a distinct role as part of a network of local inflammation. The key biomarker of allergic asthma is the IgE antibody, now considered to be the critical (gatekeeper) of the human allergic response. Given the role of the IgE molecule in the asthmatic inflammatory response, reducing its levels or inhibiting its actions on mast cells, basophils and dendritic cells could have a major impact on asthma prevention and therapy of active disease. While current therapies are available, they do not completely eliminate IgE. (Escaped) IgE can therefore still activate acute processes.Provisional Patent Application filed
*Principal Investigation

Name: Nick Giannoukakis

Department: Med-Pathology


Name: Wilson Meng

Department:


Name: Massimo Trucco

Department: Med-Pediatrics

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備